keyword
MENU ▼
Read by QxMD icon Read
search

radioembolization hcc

keyword
https://www.readbyqxmd.com/read/30057123/preoperative-strategies-to-improve-resectability-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#1
REVIEW
Francisco Tustumi, Lucas Ernani, Fabricio F Coelho, Wanderley M Bernardo, Sérgio S Junior, Jaime A P Kruger, Gilton M Fonseca, Vagner B Jeismann, Ivan Cecconello, Paulo Herman
BACKGROUND: Preoperative strategies to increase the future liver remnant are useful methods to improve resectability rates for patients with hepatocellular carcinoma (HCC). The aim of this study was to perform a systematic review and meta-analysis of the main strategies used for this purpose. METHODS: A systematic review was performed in PubMed, EMBASE, Cochrane and Scielo/LILACS. The procedures included for analysis were portal vein embolization or ligation (PVE/PVL), sequential transarterial embolization and PVE (TACE + PVE), radioembolization (RE) and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS)...
July 26, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29998020/viral-hepatitis-associated-hepatocellular-carcinoma-outcomes-with-yttrium-90-radioembolization
#2
Jessica M Frakes, Yazan A Abuodeh, Arash O Naghavi, Michelle I Echevarria, Ravi Shridhar, Mark Friedman, Richard Kim, Ghassan El-Haddad, Bela Kis, Benjamin Biebel, Jennifer Sweeney, Junsung Choi, Daniel Anaya, Anna R Giuliano, Sarah E Hoffe
Background: Viral associated (VA) malignancies have recently been correlated with improved outcomes. We sought to evaluate outcomes of patients with hepatocellular carcinoma (HCC) with and without viral hepatitis (hepatitis B and C) treated with lobar yttrium-90 radioembolization (Y-90 RE). Methods: After IRB approval, an institutional database of patients with HCC who received RE between 2009-2014 was queried and 99 patients were identified that received a total of 122 lobar RE...
June 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29976149/trans-arterial-radioembolization-for-intermediate-advanced-hepatocellular-carcinoma-a-budget-impact-analysis
#3
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Irene Bargellini, Sherrie Bhoori, Roberto Cioni, Antonio Facciorusso, Rita Golfieri, Annagiulia Gramenzi, Vincenzo Mazzaferro, Cristina Mosconi, Francesca Ponziani, Rodolfo Sacco, Franco Trevisani, Rosanna Tarricone
BACKGROUND: Trans-arterial radio-embolization (TARE) is an emerging treatment for the management of hepatocellular carcinoma (HCC). TARE may compete with systemic chemotherapy, sorafenib, in intermediate stage patients with prior chemoembolization failure or advanced patients with tumoral macrovascular invasion with no extra-hepatic spread and good liver function. We performed a budget impact analysis (BIA) evaluating the expected changes in the expenditure for the Italian Healthcare Service within scenarios of increased utilization of TARE in place of sorafenib over the next five years...
July 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29962026/spect-ct-image-based-dosimetry-for-yttrium-90-radionuclide-therapy-application-to-treatment-response
#4
Peter S Potrebko, Ravi Shridhar, Matthew C Biagioli, William F Sensakovic, George Andl, Jan Poleszczuk, Timothy H Fox
This work demonstrates the efficacy of voxel-based 90 Y microsphere dosimetry utilizing post-therapy SPECT/CT imaging and applies it to the prediction of treatment response for the management of patients with hepatocellular carcinoma (HCC). A 90 Y microsphere dosimetry navigator (RapidSphere) within a commercial platform (Velocity, Varian Medical Systems) was demonstrated for three microsphere cases that were imaged using optimized bremsstrahlung SPECT/CT. For each case, the 90 Y SPECT/CT was registered to follow-up diagnostic MR/CT using deformable image registration...
July 1, 2018: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/29951364/post-locoregional-therapy-treatment-imaging-in-hepatocellular-carcinoma-patients-a-literature-based-review
#5
REVIEW
Shamar Young, Andrew J Taylor, Tina Sanghvi
Imaging plays a crucial role in the diagnosis of hepatocellular carcinoma (HCC) as well as in determining treatment efficacy, or complications, following therapy. Unlike other cancers, HCC is most commonly treated by locoregional therapies (LRTs) such as thermal ablation, transarterial chemoembolization, and transarterial radioembolization. These treatments can lead to changes on imaging that make determination of residual/recurrent disease difficult. This literature-based review discusses the expected postimaging findings following LRT...
June 28, 2018: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29951363/hepatocellular-carcinoma-diagnosis-treatment-algorithms-and-imaging-appearance-after-transarterial-chemoembolization
#6
REVIEW
Patrick Vande Lune, Ahmed K Abdel Aal, Sergio Klimkowski, Jessica G Zarzour, Andrew J Gunn
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, with incidence increasing worldwide. Unfortunately, the overall prognosis for patients with HCC is poor and many patients present with advanced stages of disease that preclude curative therapies. Diagnostic and interventional radiologists play a key role in the management of patients with HCC. Diagnostic radiologists can use contrast-enhanced computed tomography (CT), magnetic resonance imaging, and ultrasound to diagnose and stage HCC, without the need for pathologic confirmation, by following established criteria...
June 28, 2018: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29948107/radioembolization-with-90-y-glass-microspheres-for-hepatocellular-carcinoma-significance-of-pretreatment-11-c-acetate-and-18-f-fdg-pet-ct-and-posttreatment-90-y-pet-ct-in-individualized-dose-prescription
#7
Chi Lai Ho, Sirong Chen, Shing Kee Cheung, Yim Lung Leung, Kam Chau Cheng, Ka Nin Wong, Yuet Hung Wong, Thomas Wai Tong Leung
PURPOSE: The aim of this study was to establish an algorithm for the prescription of 90 Y glass microsphere radioembolization (90 Y-GMRE) of HCC in individual patients based on the relationship between tumour dose (TD) and response validated by 90 Y PET/CT dosimetry and dual-tracer PET/CT metabolic parameters. METHODS: The study group comprised 62 HCC patients prospectively recruited for 90 Y-GMRE who underwent pretreatment dual-tracer (11 C-acetate and 18 F-FDG) PET/CT as surrogate markers of HCC cellular differentiation...
June 11, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29948005/radioembolization-super-survivors-extended-survival-in-non-operative-hepatocellular-carcinoma
#8
Andrew C Gordon, Ahmed Gabr, Ahsun Riaz, Omar M Uddin, Nadine Abouchaleh, Rehan Ali, Joseph Kallini, Riad Salem, Robert J Lewandowski
PURPOSE: To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). MATERIALS AND METHODS: Sixty-seven "Super Survivors" (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003-2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter...
June 12, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29931385/correction-to-radioembolization-for-hepatocellular-carcinoma-arising-in-the-setting-of-a-congenital-extrahepatic-portosystemic-shunt-abernethy-malformation
#9
Thomas Kroencke, Marcus Murnauer, Frank Alexander Jordan, Vera Blodow, Hannes Ruhnke, Tina Schaller, Bruno Märkl
Table 1, which appears below, was inadvertently left out of the published article.
June 21, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29901488/decrease-in-total-lesion-glycolysis-and-survival-after-yttrium-90-radioembolization-in-poorly-differentiated-hepatocellular-carcinoma-with-portal-vein-tumour-thrombosis
#10
Luca Filippi, Giovan G Di Costanzo, Antonio D'Agostini, Raffaella Tortora, Giuseppe Pelle, Roberto Cianni, Orazio Schillaci, Oreste Bagni
PURPOSE: This study aims to evaluate the prognostic role of the decrease in total lesion glycolysis (TLG) assessed by fluorine-18-fluorodeoxyglucose (F-FDG) PET-computed tomography (CT) 1 month after yttrium-90-radioembolization (Y-RE) in patients affected by hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT). PATIENTS AND METHODS: Twenty-one patients with histologically proven poorly differentiated HCC and evidence of PVTT at the enhanced multislice CT underwent Y-RE...
June 12, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29872894/transarterial-radioembolization-following-chemoembolization-for-unresectable-hepatocellular-carcinoma-response-based-on-apparent-diffusion-coefficient-change-is-an-independent-predictor-for-survival
#11
Elisabeth G Klompenhouwer, Raphaëla C Dresen, Chris Verslype, Annouschka Laenen, Lawrence Bonne, Vincent Vandecaveye, Geert Maleux
PURPOSE: To evaluate whether response based on contrast-enhanced magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) change at diffusion-weighted MRI after transarterial radioembolization (TARE) can predict survival, in patients with prior transarterial chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). METHODS: We identified all patients who received DEB-TACE prior to TARE for HCC between 2007 and 2016...
June 5, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29845347/y-90-radioembolization-combined-with-a-pd-1-inhibitor-for-advanced-hepatocellular-carcinoma
#12
Eric Wehrenberg-Klee, Lipika Goyal, Matthew Dugan, Andrew X Zhu, Suvranu Ganguli
Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs' overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492-2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy...
May 29, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29843996/radioembolization-for-hepatocellular-carcinoma-a-nationwide-10-year-experience
#13
Samer Tohme, Patrick Bou Samra, Christof Kaltenmeier, Alexis P Chidi, Patrick R Varley, Allan Tsung
PURPOSE: To examine the US nationwide experience with transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) in the years 2003-2012 and the prognostic factors associated with overall survival. MATERIALS AND METHODS: A retrospective cohort study from the National Cancer Database included 110,139 adult patients with HCC between 2003 and 2012, of whom 1,222 received TARE. Primary outcome of interest was mortality after treatment. Univariate and multivariate analyses for factors predicting mortality were performed for 961 patients treated between 2003 and 2011...
July 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29721125/contrast-enhanced-ultrasound-identifies-early-extrahepatic-collateral-contributing-to-residual-hepatocellular-tumor-viability-after-transarterial-chemoembolization
#14
Sriharsha Gummadi, Maria Stanczak, Andrej Lyshchik, Flemming Forsberg, Colette M Shaw, John R Eisenbrey
The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy including percutaneous ablation and transarterial chemo- and radioembolization. While monitoring for tumor response after transarterial chemoembolization is crucial, current imaging strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy. We present a case in which contrast-enhanced ultrasound identified a specific extra-hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting with directed transarterial management...
June 2018: Radiology case reports
https://www.readbyqxmd.com/read/29718791/radioembolization-in-advanced-hepatocellular-carcinoma
#15
Ahsun Riaz, Robert Lewandowski, Riad Salem
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
July 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29705239/reply-to-validation-of-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#16
LETTER
Carlo Sposito, Carlo Spreafico, Vincenzo Mazzaferro
No abstract text is available yet for this article.
July 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29675774/radioembolization-for-hepatocellular-carcinoma-arising-in-the-setting-of-a-congenital-extrahepatic-portosystemic-shunt-abernethy-malformation
#17
Thomas Kroencke, Marcus Murnauer, Frank Alexander Jordan, Vera Blodow, Hannes Ruhnke, Tina Schaller, Bruno Märkl
In a 50-year-old male with an incidentally discovered hepatocellular carcinoma, a congenital extrahepatic portosystemic shunt with the absence of the portal vein (Abernethy syndrome) was diagnosed by imaging. This study aims to discuss the variant anatomy relevant to this splanchnic vascular malformation, review its association with the development of liver neoplasms, and report the safety and efficacy of TARE followed by resection for a HCC arising in this rare condition.
August 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29661994/baseline-apparent-diffusion-coefficient-as-a-predictor-of-response-to-liver-directed-therapies-in-hepatocellular-carcinoma
#18
Andrew Niekamp, Reham Abdel-Wahab, Joshua Kuban, Bruno C Odisio, Armeen Mahvash, Manal M Hassan, Aliya Qayyum, Ahmed Kaseb, Rahul A Sheth
Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed...
April 14, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29659390/combined-18f-fluoroethylcholine-pet-ct-and-99mtc-macroaggregated-albumin-spect-ct-predict-survival-in-patients-with-intermediate-stage-hepatocellular-carcinoma
#19
Markus Hartenbach, Stefan Weber, Magdalena Pilz, Sabrina Hartenbach, Mathias J Zacherl, Philipp M Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Alexander R Haug, Nathalie L Albert
AIM: The aim of this study was to retrospectively analyze the prognostic value of combined Tc-macroaggregated albumin (MAA) SPECT/CT and [F]-fluoroethylcholine (FEC) PET/CT before radioembolization for survival of patients with intermediate-stage hepatocellular carcinoma. METHODS: Twenty-four patients with known hepatocellular carcinoma Barcelona Clinic Liver Cancer stage B were eligible for this analysis. All patients were scheduled for radioembolization and received a pretherapeutic [F]FEC PET/CT scan as well as Tc-MAA SPECT/CT for hepatopulmonary shunting...
July 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29651580/hepatotoxic-dose-thresholds-by-positron-emission-tomography-after-yttrium-90-radioembolization-of-liver-tumors-a-prospective-single-arm-observational-study
#20
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To define a threshold radiation dose to non-tumoral liver from 90 Y radioembolization that results in hepatic toxicity using pair-production PET. MATERIALS AND METHODS: This prospective single-arm study enrolled 35 patients undergoing radioembolization. A total of 34 patients (27 with HCC and 7 with liver metastases) were included in the final analysis. Of 27 patients with underlying cirrhosis, 22 and 5 patients were Child-Pugh A and B, respectively. Glass and resin microspheres were used in 32 (94%) and 2 (6%) patients, respectively...
April 12, 2018: Cardiovascular and Interventional Radiology
keyword
keyword
160523
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"